Agenus
| Company type | Public |
|---|---|
| Nasdaq: AGEN Russell 2000 Component | |
| Industry | |
| Founded | 1994 |
| Founders | Garo H. Armen, Pramod K. Srivastava |
| Headquarters | 3 Forbes Road, Lexington, Massachusetts, USA |
Key people |
|
| Revenue | US$ 80.0 million (2025 YTD) |
| US$ 7.5 million (2025 YTD) | |
| Total assets | US$ 233.9 million (2025) |
| Total equity | US$ -280.9 million (2025) |
| Website | www.agenusbio.com |
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.